Abstract
rhTSH can be used, instead of withdrawal of thyroid hormone, for patients who have undergone total or near total thyroidectomy to investigate the presence of the remnant thyroid, recurrence, and metastatic lesions. rhTSH is considered very beneficial because it has diagnostic ability equal to the conventional method, does not damage QOL due to hypothyroidism, and can reduce the dose of exposure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mazzaferri EL, Robbins RJ, Spencer CA et al (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433–1441 (SR<RS>)
Eustatia-Rutten CF, Smit JW, Romijn JA et al (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol 61:61–74 (SR<PS>)
Taïeb D, Sebag F, Cherenko M et al (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol 71:115–123 (RCT)
Pacini F, Ladenson PW, Schlumberger M et al (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932 (RCT)
Hoftijzer HC, Bax JJ, Heemstra KA et al (2009) Short-term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinoma. Eur J Clin Invest 39:204–210 (PS)
Botella-Carretero JI, Galán JM, Caballero C et al (2003) Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 10:601–610 (PS)
Botella-Carretero JI, Gómez-Bueno M, Barrios V et al (2004) Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 11:345–356 (PS)
Karanikas G, Schütz M, Szabo M et al (2004) Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. Am J Nephrol 24:41–45 (PS)
Münte TF, Lill C, Otting G et al (2004) Cognitive changes in short-term hypothyroidism assessed with event-related brain potentials. Psychoneuroendocrinology 29:1109–1118 (PS)
Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803 (Others)
Pacini F, Molinaro E, Castagna MG et al (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668–3673 (RS)
Sorvillo F, Mazziotti G, Carbone A et al (2003) Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue. J Clin Endocrinol Metab 88:4818–4822 (PS)
Tuttle RM, Fleisher M, Francis GL et al (2002) Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737–1742 (RS)
Sisson JC, Shulkin BL, Lawson S (2003) Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. J Nucl Med 44:898–903 (RS)
Hänscheid H, Lassmann M, Luster M et al (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648–654 (PS)
Haugen BR, Pacini F, Reiners C et al (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877–3885 (RCT)
Pilli T, Brianzoni E, Capoccetti F et al (2007) A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546 (RCT)
Tuttle RM, Brokhin M, Omry G et al (2008) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764–770 (RS)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Japan
About this chapter
Cite this chapter
Kinuya, S., Shigematsu, N., Noguchi, Y., Higashi, T. (2013). CQ44. What Is the Application, Effect and Safety of Recombinant Human Thyroid Stimulating Hormone (rhTSH)?. In: Takami, H., Ito, Y., Noguchi, H., Yoshida, A., Okamoto, T. (eds) Treatment of Thyroid Tumor. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54049-6_59
Download citation
DOI: https://doi.org/10.1007/978-4-431-54049-6_59
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54048-9
Online ISBN: 978-4-431-54049-6
eBook Packages: MedicineMedicine (R0)